Drug Trial Radar · NCT03471871
Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
Last checked: Nov 20, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Feb 21, 2018
Primary completion
Aug 3, 2018
Study completion Aug 3, 2018
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Purdue Pharma LP
- First posted
- Mar 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will be conducted to determine whether lemborexant as compared to placebo decreases the peripheral oxygen saturation during total sleep time in healthy adult and elderly participants after a single dose of treatment and to determine whether it increases the apnea-hypopnea index after single and multiple doses of treatment in adult and elderly participants with mild obstructive sleep apnea (OSA).
Conditions
- Obstructive Sleep Apnea
- Healthy Subjects
Interventions
PlaceboDrug
HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
Lemborexant 10 mgDrug
HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Lemborexant 25 mgDrug
HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
PlaceboDrug
OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Lemborexant 10 mgDrug
OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of TreatmentTime frame: Day 1
- OSA Cohort: Apnea-Hypopnea Index (AHI) on Day 8 of TreatmentTime frame: Day 8
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
PACT
Glendale, Arizona
Pulmonary Associates, PA
Phoenix, Arizona
Pacific Research Network. LLC
San Diego, California
PAB Clinical Research
Brandon, Florida
Research Centers of America
Hollywood, Florida
Neurotrials Research, Inc
Atlanta, Georgia
The Center for Sleep & Wake Disorders
Chevy Chase, Maryland
Advarra
Columbia, Maryland
Clinilabs Drug Development
New York, New York
CTI Clinical Research Center
Cincinnati, Ohio
Community Research
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.